Radiation Therapy for Extranodal Lymphomas
This book is devoted to sharing the knowledge and experience of expert radiation therapy (RT) for extranodal lymphomas. For that purpose, the authors provide clinical-pathological information, precise RT techniques, and treatment results, i.e., disease co
- PDF / 5,302,396 Bytes
- 110 Pages / 439.42 x 683.15 pts Page_size
- 44 Downloads / 256 Views
Keisuke Sasai Masahiko Oguchi Editors
123
Radiation Therapy for Extranodal Lymphomas
Keisuke Sasai • Masahiko Oguchi Editors
Radiation Therapy for Extranodal Lymphomas
Editors Keisuke Sasai Department of Radiation Oncology Juntendo University Faculty of Medicine Tokyo Japan
Masahiko Oguchi Department of Radiation Oncology The Cancer Institute Hospital Tokyo Japan
ISBN 978-4-431-56433-1 ISBN 978-4-431-56435-5 (eBook) DOI 10.1007/978-4-431-56435-5 Library of Congress Control Number: 2017946758 © Springer Japan 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Printed on acid-free paper This Springer imprint is published by Springer Nature The registered company is Springer Japan KK The registered company address is: Chiyoda First Bldg. East, 3-8-1 Nishi-Kanda, Chiyoda-ku, Tokyo 101-0065, Japan
Preface
The paradigm in the treatment of malignant lymphomas has shifted dynamically with recent rapid advances in systemic pharmaceutical treatment. Previously, the utility of systemic therapy was severely limited because few effective chemotherapeutic agents were available. Therefore, radiation therapy played an important role in the treatment of malignant tumors. Today, many effective agents are available, including novel molecular targeted drugs such as rituximab. Consequently, malignant lymphomas can now be cured by systemic therapy. Radiation therapy was previously very primitive. In the 1980s, tumors were usually treated using simple radiation fields. Because the tumor extent was unclear, the radiation fields had to be large. The standard treatment field for a malignant lymphoma was extremely large and the radiation doses were relatively high. Consequently, survivors developed unexpected complications, including secondary cancers and cardiovascular diseases. Therefore, many trials aimed to avoid radiation therapy for such disorders and currently
Data Loading...
